A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

NCT04466917 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor decision to early terminate the study

Conditions

Metastatic Non-small Cell Lung Cancer (NSCLC)
Non-squamous NSCLC

Interventions

DRUG: ABP 215
DRUG: Bevacizumab
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Amgen

Collaborators

[object Object]